Q3 EPS Estimate for Abeona Therapeutics Increased by Analyst

Key Points

• Zacks Small Cap has increased its Q3 2025 EPS estimate for Abeona Therapeutics from ($0.18) to ($0.17) per share, while the consensus estimate for the full year stands at ($1.16) per share.
• Abeona Therapeutics reported earnings of $1.71 per share for the last quarter, significantly exceeding the consensus estimate of ($0.39) per share, although its revenue fell short of expectations.
• Several analysts have provided mixed ratings for Abeona Therapeutics, with five analysts rating it as a "Buy" while others have adjusted price targets and ratings, indicating a diverse outlook for the stock.

Abeona Therapeutics Inc. (NASDAQ:ABEO - Free Report) - Equities research analysts at Zacks Small Cap lifted their Q3 2025 earnings per share (EPS) estimates for shares of Abeona Therapeutics in a research note issued to investors on Monday, August 18th. Zacks Small Cap analyst D. Bautz now expects that the biopharmaceutical company will earn ($0.17) per share for the quarter, up from their previous forecast of ($0.18). The consensus estimate for Abeona Therapeutics' current full-year earnings is ($1.16) per share. Zacks Small Cap also issued estimates for Abeona Therapeutics' Q4 2025 earnings at $0.10 EPS.

ABEO has been the topic of several other research reports. Stifel Nicolaus decreased their price target on Abeona Therapeutics from $21.00 to $20.00 and set a "buy" rating on the stock in a report on Friday, May 16th. Wall Street Zen lowered Abeona Therapeutics from a "hold" rating to a "sell" rating in a report on Thursday, May 15th. Alliance Global Partners restated a "buy" rating on shares of Abeona Therapeutics in a report on Thursday, May 15th. Oppenheimer increased their price target on Abeona Therapeutics from $19.00 to $20.00 and gave the company an "outperform" rating in a report on Friday, August 15th. Finally, HC Wainwright restated a "buy" rating and set a $20.00 price target on shares of Abeona Therapeutics in a report on Monday. Five equities research analysts have rated the stock with a Buy rating, According to MarketBeat, the company currently has a consensus rating of "Buy" and a consensus price target of $19.50.

Abeona Therapeutics Stock Performance

NASDAQ:ABEO opened at $7.00 on Thursday. The stock's fifty day moving average is $6.26 and its 200 day moving average is $5.77. Abeona Therapeutics has a fifty-two week low of $3.93 and a fifty-two week high of $7.54. The firm has a market capitalization of $358.96 million, a PE ratio of 10.00 and a beta of 1.55. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.90 and a current ratio of 6.73.

Abeona Therapeutics (NASDAQ:ABEO - Get Free Report) last released its quarterly earnings results on Thursday, August 14th. The biopharmaceutical company reported $1.71 earnings per share for the quarter, beating the consensus estimate of ($0.39) by $2.10. The company had revenue of $0.40 million for the quarter, compared to analysts' expectations of $21.71 million.

Insiders Place Their Bets

In other Abeona Therapeutics news, CEO Vishwas Seshadri sold 69,420 shares of the stock in a transaction on Wednesday, July 9th. The stock was sold at an average price of $5.86, for a total value of $406,801.20. Following the sale, the chief executive officer owned 1,234,341 shares in the company, valued at $7,233,238.26. This trade represents a 5.32% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Brendan M. O'malley sold 17,428 shares of the stock in a transaction on Wednesday, July 9th. The stock was sold at an average price of $5.86, for a total value of $102,128.08. Following the completion of the sale, the senior vice president owned 360,817 shares in the company, valued at approximately $2,114,387.62. The trade was a 4.61% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 231,626 shares of company stock valued at $1,430,587. Insiders own 6.90% of the company's stock.

Hedge Funds Weigh In On Abeona Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Creative Planning grew its position in shares of Abeona Therapeutics by 43.0% during the 2nd quarter. Creative Planning now owns 14,310 shares of the biopharmaceutical company's stock worth $81,000 after buying an additional 4,305 shares in the last quarter. Ameritas Investment Partners Inc. bought a new position in shares of Abeona Therapeutics during the 2nd quarter worth $25,000. Legal & General Group Plc bought a new position in shares of Abeona Therapeutics during the 2nd quarter worth $27,000. OMERS ADMINISTRATION Corp boosted its position in Abeona Therapeutics by 11.0% during the first quarter. OMERS ADMINISTRATION Corp now owns 72,200 shares of the biopharmaceutical company's stock valued at $344,000 after purchasing an additional 7,155 shares in the last quarter. Finally, Twinbeech Capital LP bought a new stake in Abeona Therapeutics during the fourth quarter valued at about $58,000. Institutional investors own 80.56% of the company's stock.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.